Manufacturing

Also, AstraZeneca announces changes to its supply chain operations; Christian Velmer appointed head of Wyeth Canada; More...

The European Commission (EC) published a preliminary report stating that competition in the pharmaceutical industry does not work as well as it should.

A recent study shows life-science companies have difficulty in planning and executing change-management practices.

When accusations fly: 'Tis better to give than to receive.

The past year saw major acquisitions attempted, completed, rejected, and stalled.

Readers provide insight into the best companies to work for as well as the ups and downs of their jobs.

While the world pulls itself out from one of the worst crises in decades, Indian pharmaceutical companies are trying to capitalize on falling company prices by increasing their takeovers.

To expand coverage amidst the economic crisis, Obama will look for ways to cut healthcare costs.

Editors' Picks of Pharmaceutical Science & Technology Innovations

China's quality approach to domestic versus exported products seems to be a lose-lose situation.

A recent Pharmaceutical Technology survey examined the level, sources, and reasons behind innovation in drug development and manufacturing. This article contains bonus online-exclusive material.

A book about pharmaceutical analysis engages the reader with history and unexpected asides.

The authors review the current regulatory framework for the selection of drug substance starting materials.

The next president and the 111th Congress might change the extent of FDA's authority.

Results from Pharmaceutical Technology's Annual Employment Survey.

Pharmaceutical Technology is pleased to recognize the winners of its Innovations in Pharma Science Awards.

New research suggests calcium carbonate tablets are stronger and less porous when manufactured using a wet, rather than a dry, granulation process.

Hundreds of pharma–biotech deals have been announced during 2008 and many of these probably began at biopartnering conferences. Susan Aldridge examines some of this year's big buyouts and mergers.

It is a universally acknowledged truth that a biotech start-up in possession of little fortune must be in want of venture capital (VC). Perhaps less well acknowledged, however, is that VC investors operate in a way consistent with being rational economic entities...

Although realized in 1983, ASTM's standrad test method for determining bacterial retention of membrane filters used for liquid filtration is still hugely beneficial to today's pharmaceutical industry.

TranScrip Partners' Flic Gabbay explains why an approach that provides expertise on an 'as needed basis' is flourishing.

You don't have to spend any time in the company of its chairman to see that there is no other Big Pharma company like Servier.

Also, Johnson & Johnson will acquire Omrix Biopharmaceuticals for $438 million; Charles River Laboratories promoted Foster Jordan to corporate senior VP of endotoxin and microbial detection products; more...

Companies at the American Association of Pharmaceutical Scieintists (AAPS) unveiled technologies, expansion plans, and services for formulation development, manufacturing, and drug delivery at the AAPS Annual Meeting and Exposition held in Atlanta last week.

During its roundtable discussion titled "Follow-On Biologic (FOB) Drugs: Framework for Competition and Continued Innovation," The Federal Trade Commission (FTC) discussed likely effects, patent issues, and regulatory exclusivity periods concerning FOBs.